Laekna to Develop and Commercialize Two Oral Akt Inhibitors with Positive Proof-of-concept Results SHANGHAI, July 31, 2018 /PRNewswire/ -- Laekna Inc., a biotechnology company headquartered in Shanghai, announced today the signing of an agreement with Novartis Pharma AG for exclusive...
from PR Newswire: //https://ift.tt/2LTT7jN
No comments:
Post a Comment